Dinutuximab (ch14.18, a mAb against tumor-associated disialoganglioside GD2) has demonstrated activity against neuroblastoma cells; however, administration of the mAb alone was insufficient to prevent tumor progression, thus both GM-CSF and IL-2 were added to augment efficacy. The gene discussed is CSF2; the disease is neuroblastoma.